Effects of Biofunctional Orange Juice on Cardiometabolic Risk Markers
- Conditions
- HypertensionPrediabetesOverweight and ObesityDyslipidemias
- Interventions
- Other: Orange juice enriched with vitamin D3 and encapsulated probioticsOther: Conventional orange juice
- Registration Number
- NCT06114576
- Lead Sponsor
- Agricultural University of Athens
- Brief Summary
The effects of orange juice enriched with vitamin D3 and encapsulated probiotics (Lacticaseibacillus casei Shirota and Lacticaseibacillus rhamnosus GG) compared to conventional orange juice on several cardiometabolic and anthropometric parameters in individuals at risk of cardiovascular disease.
- Detailed Description
This randomized, double-blind, controlled clinical trial aims to evaluate the effects of the consumption of orange juice enriched with vitamin D3 and encapsulated probiotics (Lacticaseibacillus casei Shirota and Lacticaseibacillus rhamnosus GG) compared to conventional orange juice in 50 high cardiometabolic risk volunteers. The participants must be overweight/obese with either prediabetes, and/or hypertension, and/or hyperlipidemia, and will be divided and randomly assigned into 2 groups of 25 individuals each. Participants will consume 250 ml of either orange juice enriched with vitamin D3 and encapsulated probiotics (Lacticaseibacillus casei Shirota and Lacticaseibacillus rhamnosus GG) or conventional orange juice daily for 8 weeks as an addition to their usual dietary intake. Participants will be asked to maintain their usual physical activity during the intervention period. At the beginning of the study and at 8 weeks, blood samples will be collected after 12 hours of fasting. Two-hour oral glucose tolerance test (OGTT) will be performed using a continuous glucose monitoring system at the beginning and at 8 weeks. Anthropometric measurements will be performed at the beginning and every week for 8 weeks. Basal metabolic rate (BMR) and central aortic blood pressure will be measured at the beginning, 4 weeks, and 8 weeks of intervention. Fecal samples will be collected and analyzed to study gut microbiome compositob at the intervention's beginning and at 8 weeks.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
- Body Mass Index >= 25 kg/m2
- Prediabetes [fasting blood glucose > 100 mg/dL], or/and
- Hypertension [Systolic blood pressure (SBP) > 130 mmHg or Diastolic blood pressure (DBP) > 80 mmHg], or/and
- Hyperlipidemia [total cholesterol > 200 mg/dL, and/or LDL-C > 100 mg/dL, and/or triglycerides > 150 mg/dL]
- Severe chronic disease (e.g. cardiovascular diseases, diabetes mellitus, kidney or liver diseases, endocrine conditions)
- Medication that affects glycemia such as metformin, glucocorticoids, thiazide diuretics
- Gastrointestinal disorders
- Pregnancy
- Lactation
- Alcohol abuse
- Drug dependency
- Body weight lowering medications and/or history of bariatric surgery
- Depression and other psychiatric diseases
- Cancer
- Probiotic, prebiotic, and vitamin D supplemental intake
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Orange juice enriched with vitamin D3 and encapsulated probiotics Orange juice enriched with vitamin D3 and encapsulated probiotics 250 ml of orange juice enriched with vitamin D3 and encapsulated probiotics Conventional orange juice Conventional orange juice 250 ml of conventional orange juice
- Primary Outcome Measures
Name Time Method Change in blood glucose concentrations 8 weeks Clinically significant change in blood glucose concentrations (mg/dL)
- Secondary Outcome Measures
Name Time Method Change in blood insulin concentrations 8 weeks Clinically significant change in blood insulin concentrations (μU/L)
Change in basal metabolic rate (BMR) 8 weeks Clinically significant change in basal metabolic rate (kcal/day)
Change in energy intake 8 weeks Clinically significant change in energy intake (kcal/day)
Change in blood lipids 8 weeks Clinically significant in triglycerides (mg/dL), total cholesterol (mg/dL), low-density lipoprotein (mg/dL), and high-density lipoprotein (mg/dL)
Change in central aortic blood pressure 8 weeks Clinically significant change in central pressure (mmHg)
Change in body weight 8 weeks Clinically significant change in body weight (kg)
Change in gut microbiome 8 weeks The microbial composition in fecal samples will be measured via taxonomic profiling by 16S (V3-V4 region) ribosomal RNA gene amplicon sequencing using the MiSeq Illumina platform (v3 300bp pair-end sequencing) to identify a wide diversity of microbes
Trial Locations
- Locations (1)
Agricultural University of Athens
🇬🇷Athens, Attica, Greece